Scribe and Sanofi expand genetic therapy development deal
Pharmaceutical Technology
JULY 18, 2023
Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Pharmaceutical Technology
JULY 18, 2023
Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.
Bio Pharma Dive
DECEMBER 12, 2023
Based on the work of MIT scientists, the well-funded startup is developing ways to insert large sizes of genetic material anywhere in the genome without damaging or breaking DNA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Worldwide Clinical Trials
DECEMBER 19, 2024
At the recent World Orphan Drug Congresses (WODC) in Europe and the United States, Worldwide Clinical Trials Derek Ansel , Vice President, Therapeutic Strategy Lead, Rare Disease, facilitated roundtable discussions to explore the operational challenges and ethical barriers surrounding genetic testing.
World of DTC Marketing
DECEMBER 29, 2020
OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The post How did pharma develop a vaccine so quickly?
Pharmaceutical Technology
JUNE 8, 2023
Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.
Pharmaceutical Technology
NOVEMBER 8, 2022
Fulgent Genetics has acquired clinical-stage therapeutics development firm Fulgent Pharma for a total deal price of nearly $100m. According to the deal, the purchase price, contingent on adjustments, has to be paid by Fulgent Genetics as a combination of cash on hand and its shares of common stock.
pharmaphorum
OCTOBER 12, 2022
David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.
pharmaphorum
JANUARY 26, 2023
2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.
pharmaphorum
AUGUST 10, 2020
Swiss medical data specialist Sophia Genetics has launched a platform that will sift through data generated at more than 1,000 hospitals around the world to try to work out how the COVID-19 pandemic will evolve in the coming months and years. The post Sophia Genetics launches AI tool to find COVID-19 ‘unknowns’ appeared first on.
XTalks
APRIL 21, 2023
The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.
Pharmaceutical Technology
JUNE 16, 2023
The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance life sciences.
pharmaphorum
SEPTEMBER 14, 2020
Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential.
Worldwide Clinical Trials
DECEMBER 12, 2022
Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. What are the benefits and limitations to using genetic testing?
Pharmaceutical Technology
JUNE 30, 2022
Analysing almost eight thousand tumours across 33 different cancers, researchers say this marks the first time that a framework was created to understand the role of internal factors in driving such genomic alterations. Genomic research have greatly expanded our understanding of disease pathophysiology over the years.
Pharmaceutical Technology
MAY 17, 2023
Under the deal, Prevail obtains exclusive rights to use Scribe’s CRISPR X-Editing (XE) technologies to develop the medicines. The deal will see the integration of Scribe’s new CRISPR by Design approach and Prevail’s expertise in developing genetic medicines for neurological disorders for specific genetic targets.
Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified animal models. Regeneron Pharmaceuticals is one of the leading patent filers in the generation of genetically modified animal models.
XTalks
MAY 23, 2024
One of the more intriguing developments in cancer research in recent years is the growing understanding of clonal hematopoiesis, a phenomenon where blood cells expand from a single clone due to genetic mutations. Clonal hematopoiesis increases in prevalence with age and can precede hematologic malignancies.
Worldwide Clinical Trials
FEBRUARY 6, 2023
When using genetic screening to identify clinical trial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed. Read the full article!
pharmaphorum
SEPTEMBER 12, 2022
Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. In other words, every person’s cancer has its own genetic construct. Tailored oncology.
Pharmaceutical Technology
DECEMBER 14, 2022
GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.
Pharmaceutical Technology
FEBRUARY 13, 2023
Gene therapies are an attractive way of targeting the underlying genetic mutations, but traditional approaches cannot be used while targeting mutations for Dravet Syndrome, forcing researchers to develop new ways. To tackle this, companies have developed different ways to focus on the gene.
Scienmag
MARCH 10, 2022
Scientists have developed a powerful, inclusive new tool for genomic research that boosts efforts to develop more precise treatments for many diseases by leveraging a better representation of the genetic diversity of people around the world.
pharmaphorum
JANUARY 18, 2023
In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in serious – even deadly – childhood disease, but who were apparently healthy. First, start co-development with participants early on in the process.
Scienmag
FEBRUARY 23, 2022
Researchers at the RIKEN Center for Sustainable Resource Science (CSRS) in Japan have developed a way to improve crop quality without needing to create special genetically modified plants. Rather that changing plant genomes, the new technique relies on a spray that introduces bioactive molecules into plant cells through their leaves.
pharmaphorum
NOVEMBER 27, 2022
A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs. “It would have saved me and the NHS a lot of money. .” Why do we always have to follow? Why not lead?”
pharmaphorum
JANUARY 24, 2023
Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.
Pharmaceutical Technology
APRIL 12, 2023
Repotrectinib has been developed to combat cancer resistance to existing therapies and exert consistent anti-tumor activity. Individuals that develop lung cancer with no smoking history are genetically distinct from those who develop the cancer with a smoking history.
Pharmaceutical Technology
SEPTEMBER 29, 2022
Scribe Therapeutics and Sanofi have signed a strategic partnership to expedite the development of breakthrough clustered regularly interspaced short palindromic repeats (CRISPR)-based cell therapies for cancer. Scribe is also entitled to receive potential payments worth over $1bn on meeting development and commercial milestones.
XTalks
JULY 19, 2021
Phosphorus, a leading preventative genomics company, has developed the first comprehensive preventative genetic test for consumers. The test is called GeneCompass and features medical-grade technology to provide a holistic assessment of genetic health and wellness. The Phosphorus GeneCompass test has a list price of $249.
Scienmag
NOVEMBER 3, 2020
Credit: Encarnacion/UConn Photo The advent of genome science has given researchers an unprecedented ability to understand the root causes of a host of conditions.
XTalks
NOVEMBER 10, 2020
Expeditious and accurate diagnoses are necessary for patients to access healthcare services and treatment options for rare genetic diseases. Increasing the efficiency of case analysis and interpretation is essential to providing timely care for patients with genetic diseases.
BioPharma Reporter
OCTOBER 10, 2023
Childrenâs Mercy Kansas City, an independent pediatric health organization, has become the first health care system to replace old genetic tests, such as rapid exome and chromosomal microarray analysis, with the worldâs most-advanced genomic sequencing technology from PacBio.
pharmaphorum
SEPTEMBER 16, 2022
With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas. What, then, is the solution?
Medical Xpress
NOVEMBER 8, 2022
A team of researchers at Indiana University School of Medicine has developed specialized bioinformatics software designed to identify rare genetic variants in whole-genome sequencing studies. Zilin Li, Ph.D.,
Pharmaceutical Technology
JUNE 4, 2023
AAV genomes are highly compact, with overlapping coding regions, alternate splicing schemes, and multiple transcription initiation codons. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins. Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders.
Scienmag
JANUARY 11, 2022
A new study has helped to shine light on the genetic pathways underlying obesity. The findings could help develop more personalised ways to help people maintain a healthy weight. The work is the largest study of its kind looking at genomics and levels of metabolites – the molecules produced when the body breaks down food. […].
pharmaphorum
NOVEMBER 23, 2021
Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for whole genome sequencing (WGS) has reached a level at which its national rollout on the NHS may someday become a reality. Only when genomic databases are diverse can we ensure that we all benefit equally.
XTalks
SEPTEMBER 30, 2020
The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. Casanova’s lab is now searching for the genetic driver behind the autoantibodies. percent of men.
STAT News
OCTOBER 3, 2022
By developing new techniques for working with ancient genetic material — which is often heavily degraded and contaminated by microorganisms — he led teams that sequenced the genome of the Neanderthal, and discovered a previously unknown hominin, Denisova.
Pharmaceutical Technology
MARCH 28, 2023
Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.
Pharmaceutical Technology
FEBRUARY 15, 2023
According to GlobalData, there are 140+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of gene therapy delivery using viral vectors. Sanofi is one of the leading patent filers working with viral vectors.
STAT News
FEBRUARY 22, 2023
The Cambridge biotech company announced Wednesday that it will partner with Life Edit Therapeutics to develop potentially permanent treatments for rare genetic diseases and other conditions. Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines.
XTalks
APRIL 15, 2021
New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.
XTalks
MARCH 21, 2025
The company also launched Learn NPC, an awareness campaign aimed at improving early diagnosis and supporting families affected by this rare genetic disorder. This enhancement supports large-scale initiatives like the GUARDIAN study, which aims to screen around 100,000 babies for over 460 genetic conditions.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content